Efficacy of Yttrium-90 Transarterial Radioembolisation in Advanced Hepatocellular Carcinoma: An Experience With Hybrid Angio-Computed Tomography and Glass Microspheres
- PMID: 38283702
- PMCID: PMC10819781
- DOI: 10.1016/j.jceh.2023.101342
Efficacy of Yttrium-90 Transarterial Radioembolisation in Advanced Hepatocellular Carcinoma: An Experience With Hybrid Angio-Computed Tomography and Glass Microspheres
Abstract
Background: Hepatocellular carcinoma is one of the most common malignancies worldwide. Transarterial radioembolisation (TARE) involves selective intra-arterial administration of microspheres loaded with a radioactive compound like Yttrium-90 (Y-90). Conventionally, C-arm-based cone-beam computed tomography has been extensively used during TARE. However, angio-computed tomography (CT) is a relatively new modality which combines the advantages of both fluoroscopy and fCT. There is scarce literature detailing the use of angio-CT in Y90 TARE.
Methods: This was a retrospective study of primary liver cancer cases in which the TARE procedure was done from November 2017 to December 2021. Glass-based Y-90 microspheres were used in all these cases. All the cases were performed in the hybrid angio-CT suite. A single photon emission computed tomography-computed comography (SPECT-CT) done postplanning session determined the lung shunt fraction and confirmed the accurate targeting of the lesion. Postdrug delivery, positron emission tomography-computed tomography (PET-CT) was obtained to confirm the distribution of the Y-90 particles. The technical success, median follow-up, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were recorded.
Results: A total of 56 hepatocellular carcinoma patients underwent TARE during this period, out of which 36 patients (30 males and 6 females) underwent Y90 TARE. The aetiology of cirrhosis included non-alcoholic steatohepatitis (NASH) (11), hepatitis C (HCV) (11), hepatitis B (HBV) (9), metabolic dysfunction and alcohol-associated liver disease (MetALD) (2), alcoholic liver disease (ALD) (1), cryptogenic (1), and autoimmune hepatitis (AIH) (1). The technical success was 100 % and the median follow-up was 7 months (range: 1-32 months). The median OS was 15 months (range 10.73-19.27 months; 95 % CI) and the median local PFS was 4 months (range 3.03-4.97 months; 95 % CI). The ORR (best response, CR + PR) was 58 %. No major complications were seen in this study.
Conclusion: TARE is a viable option for liver cancer in all stages, but more so in the advanced stages. The use of angio-CT in TARE aids in the precise delivery of the particles to the tumour and avoids non-target embolisation.
Keywords: HCC; TARE; Yttrium-90; angio-CT; glass microspheres.
© 2023 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.
Similar articles
-
For Hepatocellular Carcinoma Treated with Yttrium-90 Microspheres, Dose Volumetrics on Post-Treatment Bremsstrahlung SPECT/CT Predict Clinical Outcomes.Cancers (Basel). 2023 Jan 20;15(3):645. doi: 10.3390/cancers15030645. Cancers (Basel). 2023. PMID: 36765603 Free PMC article.
-
18F-FDG PET/CT predicts survival after 90Y transarterial radioembolization in unresectable hepatocellular carcinoma.Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1215-1222. doi: 10.1007/s00259-017-3653-0. Epub 2017 Feb 23. Eur J Nucl Med Mol Imaging. 2017. PMID: 28233086
-
Accuracy and reproducibility of a cone beam CT-based virtual parenchymal perfusion algorithm in the prediction of SPECT/CT anatomical and volumetric results during the planification of radioembolization for HCC.Eur Radiol. 2023 May;33(5):3510-3520. doi: 10.1007/s00330-023-09390-w. Epub 2023 Jan 18. Eur Radiol. 2023. PMID: 36651956
-
Hybrid angiography-CT for transarterial radioembolization: a pictorial essay.Abdom Radiol (NY). 2021 Jun;46(6):2850-2854. doi: 10.1007/s00261-020-02914-8. Epub 2021 Jan 4. Abdom Radiol (NY). 2021. PMID: 33394098 Review.
-
Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma.Adv Ther. 2016 May;33(5):699-714. doi: 10.1007/s12325-016-0324-7. Epub 2016 Apr 2. Adv Ther. 2016. PMID: 27039186 Free PMC article. Review.
Cited by
-
Editorial: Role of Yttrium-90 Transarterial Radioembolisation in Advanced Hepatocellular Carcinoma.J Clin Exp Hepatol. 2024 May-Jun;14(3):101402. doi: 10.1016/j.jceh.2024.101402. Epub 2024 Mar 19. J Clin Exp Hepatol. 2024. PMID: 38586435 No abstract available.
References
LinkOut - more resources
Full Text Sources
Research Materials